Arrowhead Pharmaceuticals (ARWR) Share-based Compensation (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Share-based Compensation came in at $16.7 million in Q1 2026, up 4.01% YoY from $16.0 million in Q1 2025, and down 13.94% on a QoQ basis from $19.4 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Share-based Compensation (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Share-based Compensation data on file, last reported at $16.7 million in Q1 2026.
- Quarterly Share-based Compensation rose 4.01% year-over-year to $16.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.2 million (up 0.61% YoY) and the FY2025 annual result came in at $63.4 million, down 14.33% from the prior year.
- Share-based Compensation fell to $16.7 million in Q1 2026, from $19.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $33.4 million in Q2 2022 to a low of $13.0 million in Q2 2025.
- A 5-year average of $19.6 million and a median of $19.1 million in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 53.72% — and 2023, when it tumbled 40.26%.
- Tracing ARWR's Share-based Compensation over 5 years: stood at $19.4 million in 2022, then grew by 1.57% to $19.7 million in 2023, then dropped by 22.77% to $15.2 million in 2024, then gained by 27.37% to $19.4 million in 2025, then slipped by 13.94% to $16.7 million in 2026.
- The last three Share-based Compensation figures came in at $16.7 million (Q1 2026), $19.4 million (Q4 2025), and $19.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | 14.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.87 Mn |
| Jun 30, 2026 | 14.87 Mn |
| Mar 31, 2026 | 16.67 Mn |
| Mar 31, 2026 | 16.67 Mn |
| Dec 31, 2025 | 19.37 Mn |
| Dec 31, 2025 | 19.37 Mn |
| Sep 30, 2025 | 19.09 Mn |
| Sep 30, 2025 | 19.09 Mn |
| Jun 30, 2025 | 13.04 Mn |
| Jun 30, 2025 | 13.04 Mn |
| Mar 31, 2025 | 16.03 Mn |
| Mar 31, 2025 | 16.03 Mn |
| Dec 31, 2024 | 15.21 Mn |
| Dec 31, 2024 | 15.21 Mn |
| Sep 30, 2024 | 19.47 Mn |
| Sep 30, 2024 | 19.47 Mn |
| Jun 30, 2024 | 17.05 Mn |
| Jun 30, 2024 | 17.05 Mn |
| Mar 31, 2024 | 17.75 Mn |
| Mar 31, 2024 | 17.75 Mn |